Antares Pharma (NASDAQ:ATRS) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Friday, BidAskClub reports.
Several other analysts have also recently issued reports on ATRS. Piper Sandler reiterated an “overweight” rating and issued a $5.00 price objective on shares of Antares Pharma in a research note on Sunday, June 21st. HC Wainwright reiterated a “buy” rating on shares of Antares Pharma in a research note on Monday, August 10th. LADENBURG THALM/SH SH reiterated a “buy” rating and issued a $7.00 price objective on shares of Antares Pharma in a research note on Sunday, June 21st. Zacks Investment Research upgraded Antares Pharma from a “hold” rating to a “buy” rating and set a $3.25 price objective on the stock in a research note on Wednesday. Finally, Raymond James reiterated a “buy” rating on shares of Antares Pharma in a research note on Thursday, October 1st. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Antares Pharma currently has an average rating of “Buy” and an average target price of $5.15.
NASDAQ:ATRS opened at $3.28 on Friday. The company has a quick ratio of 2.41, a current ratio of 2.90 and a debt-to-equity ratio of 0.71. The stock’s fifty day moving average is $2.77 and its two-hundred day moving average is $2.73. Antares Pharma has a 52 week low of $1.60 and a 52 week high of $5.13. The stock has a market capitalization of $544.79 million, a price-to-earnings ratio of 82.02 and a beta of 1.24.
We’re just getting word of this… an all new way to trade – before the bell rings on Wall Street – allowing traders to achieve up to 1,139% return…
Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $0.01 EPS for the quarter. Antares Pharma had a return on equity of 10.58% and a net margin of 4.04%. The company had revenue of $32.38 million for the quarter, compared to analysts’ expectations of $29.25 million. On average, sell-side analysts expect that Antares Pharma will post 0.06 EPS for the current fiscal year.
A number of large investors have recently bought and sold shares of ATRS. Costello Asset Management INC purchased a new position in Antares Pharma in the second quarter valued at $28,000. Paloma Partners Management Co purchased a new position in Antares Pharma in the first quarter valued at $40,000. Kelman Lazarov Inc. purchased a new position in Antares Pharma in the second quarter valued at $41,000. ProShare Advisors LLC purchased a new position in Antares Pharma in the second quarter valued at $61,000. Finally, Jane Street Group LLC purchased a new position in Antares Pharma in the second quarter valued at $62,000. 42.96% of the stock is currently owned by hedge funds and other institutional investors.
Antares Pharma Company Profile
Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company’s injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Further Reading: Why do company’s buyback their stock?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Best Growth Stocks – Best Stocks to Buy Now
The stock market has been growing since the New York Stock Exchange opened its doors in 1817. Sometimes, a stock will outpace the rest of the market in terms of growth. These skyrocketing securities—or the ones that analysts expect to skyrocket—are called growth stocks.
What Every Investor Needs to Know About Growth Stocks
Growth stocks are a great opportunity for an investor to make money in the stock market, but you’ve got to know what you’re going to buy or sell. A good understanding of growth stocks will help you get there.
At the beginning of a bull market, you can almost choose stocks randomly and find yourself a winner. Now that we are entering the ninth year of the current bull market, growth stocks have appreciated considerably and it’s becoming far more challenging to find stocks with real opportunities for appreciation.
Growth companies are still largely outperforming their value counterparts in the United States and the rest of the world largely because of low interest rates, improved corporate earnings and global economic growth. Over the last five years, the S&P 500 Growth Index has returned 14.22% per year. During the same time, the S&P 500 Value Index returned just 12.94%.
Now that the bull market is now nearly a decade old, stocks have become very expensive. Value investors are largely sitting on the sidelines and growth investors are having a hard time figuring out where the remaining growth opportunities exist.
If you are looking for growth stocks in an increasingly small field, we have identified the 10 best growth stocks to buy right now based on their expected earnings growth over the next several years. These companies are all growing rapidly and will likely see double-digit earnings growth next year.
